Skip to main content
Equibles
MXCT logo

MXCT · Maxcyte, Inc. · Webcasts, Transcripts & Audio

Track MXCT — free

Use MXCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MXCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.08 +0.01 (+0.93%) At close · Oct 5
Rebalance outlook locked
Market Cap
$120.75M
Shares
103.21M
Volume · Oct 5 194.91K Avg daily vol (3M) 715.19K

Maxcyte, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Maxcyte, Inc. (MXCT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲5% $10.64M −$6.43M '22 Q3 22-11-09 ▲22.4% $12.42M −$4.81M '22 Q4 23-03-06 ▼26% $8.58M −$10.88M '23 Q1 23-05-10 ▼5.9% $9.04M −$10.51M '23 Q2 23-08-09 ▼24.8% $8.00M −$11.25M '23 Q3 23-11-08 ▲26.1% $15.66M −$5.28M '23 Q4 24-03-12 ▲32.3% $11.34M −$9.53M '24 Q1 24-05-07 ▲15.3% $10.43M −$9.38M '24 Q2 24-08-06 ▲2% $8.16M −$11.56M '24 Q3 24-11-06 ▼44.5% $8.69M −$10.60M '24 Q4 25-03-11 ▼8.4% $10.39M −$10.26M '25 Q1 25-05-07 ▼18.4% $8.51M −$12.36M '25 Q2 25-08-06 ▼16.4% $6.83M −$12.42M '25 Q3 25-11-12 ▼16% $7.30M −$9.60M '25 Q4 26-03-24 ▼7.1% $9.65M −$4.75M '26 Q1 26-05-12 LATEST ▼14.5% $7.27M −$8.87M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Maxcyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript
Confident tone Instrument placements and DTX adoption Genentech multi-platform partnership Return to revenue growth in H2 2026
Revenue
$7.27M
▼ 14.5% YoY
Diluted EPS
$-0.08
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Maxcyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
Positive tone SPL Partner Pipeline and Registrational Programs Core Revenue and SPL Program Mix SeQure Off-Target Assay Services
Revenue
$9.65M
▼ 7.1% YoY
Diluted EPS
$-0.04
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Maxcyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
Balanced tone 2026 Revenue Guidance Cell Therapy Market Outlook ExPERT DTX Product Launch
Revenue
$7.30M*
▼ 16% YoY
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Maxcyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
Positive tone SPL Partnership Pipeline Long-Term Value and Growth Strategy Gross Margin and Product Mix
Revenue
$6.83M
▼ 16.4% YoY
Diluted EPS
$-0.12
Gross margin
76.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Maxcyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
Cautious tone SeQure Dx integration Clinical program progress and pivotal studies CASGEVY commercial momentum (Vertex)
Revenue
$8.51M
▼ 18.4% YoY
Diluted EPS
$-0.12
Gross margin
82.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Maxcyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
Positive tone SeQure Dx integration and revenue Cell and gene therapy market trends SPL portfolio and pipeline
Revenue
$10.39M
▼ 8.4% YoY
Diluted EPS
$-0.10
Gross margin
85.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Maxcyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript
Positive tone SeQure Dx Acquisition and Integration 2025 Guidance and Quarterly Cadence SPL Portfolio Expansion
Revenue
$8.69M*
▼ 44.5% YoY
Gross margin
73.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Maxcyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
Confident tone SPL Pipeline Growth & New Signings Core Revenue & 2024 Guidance Increase CASGEVY Commercial Milestone Opportunity
Revenue
$8.16M
▲ 2% YoY
Diluted EPS
$-0.11
Gross margin
76.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Maxcyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
Positive tone Cell therapy market opportunity CASGEVY / Vertex commercial launch VLX portfolio realignment
Revenue
$10.43M
▲ 15.3% YoY
Diluted EPS
$-0.09
Gross margin
85.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Maxcyte, Inc. (MXCT) Q1 2024 Earnings Call
Revenue
$11.34M
▲ 32.3% YoY
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Maxcyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript
Positive tone Strategic Platform Licenses (SPL) portfolio growth CASGEVY commercial launch and royalties Leadership transition and strategic priorities
Revenue
$15.66M*
▲ 26.1% YoY
Gross margin
90.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Maxcyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript
Revenue
$8.00M
▼ 24.8% YoY
Diluted EPS
$-0.11
Gross margin
90.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Maxcyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript
Revenue
$9.04M
▼ 5.9% YoY
Diluted EPS
$-0.10
Gross margin
84.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Maxcyte, Inc. (MXCT) Q1 2023 Earnings Call Transcript
Revenue
$8.58M
▼ 26% YoY
Diluted EPS
$-0.11
Gross margin
88.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Maxcyte, Inc. (MXCT) Q4 2022 Earnings Call Transcript
Revenue
$12.42M*
▲ 22.4% YoY
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Maxcyte, Inc. (MXCT) Q3 2022 Earnings Call Transcript
Revenue
$10.64M
▲ 5% YoY
Diluted EPS
$-0.06
Gross margin
87.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Maxcyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript
Revenue
$9.61M
▲ 35.2% YoY
Diluted EPS
$-0.08
Gross margin
88.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Maxcyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript
Revenue
$11.59M
▲ 78.4% YoY
Diluted EPS
$-0.04
Gross margin
90.8%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Maxcyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript
Revenue
$10.15M*
Gross margin
87.9%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Maxcyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript
Revenue
$10.14M
▲ 49.9% YoY
Diluted EPS
$-0.03
Gross margin
90.7%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-09-17
Maxcyte, Inc. (MXCT) Q2 2021 Earnings Call Transcript
Revenue
$7.11M
▲ 38% YoY
Diluted EPS
$-0.05
Gross margin
89.0%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 webcasts
Key facts CIK 1287098 CUSIP 57777K106 13F (30d) 1 filings 1 filers Visit website Investor relations